New and Revised Draft GMP Guidances FDA is planning to publish 2017

Recommendation
27/28 May 2025
Supervision of the Pharmaceutical Quality System: Challenges and Opportunities
The U.S. Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) has published a Guidance Agenda with planned new and revised Draft Guidances for the calendar year 2017. Amongst these documents are a few which might be interesting for the GMP area, for example:
- Bioanalytical Method Validation; Revised Draft
- Container Closure Systems for Packaging Human Drugs and Biologics; Revised Draft
- Drug Master Files; Revised Draft
- Visual Inspection of Injectable Drug Products
- Current Good Manufacturing Practice for Medical Gases; Revised Draft
- Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products; Revised Draft
- Field Alert Report Submission
- Repackaging of Certain Drug Products by Pharmacies and Outsourcing Facilities
The items of the Guidance Agenda: New & Revised Draft Guidances CDER is Planning to Publish During Calendar Year 2017 reflect draft and revised draft guidances under development as of the date of FDA's posting. So there might be more to come.
Related GMP News
07.05.2025FDA is extending its Quality Management Maturity Programme
30.04.2025FDA Warning Letter on missing Audit Trails and Raw Data Review
23.04.2025New WHO Guideline Package: TRS 1060 published
16.04.2025EMA: QPs must provide a written final Assessment and Approval of Third-Party Audit Reports
15.04.2025Strategic Report published by the Critical Medicines Alliance
09.04.2025EMA's Plans for the next three Years